CDK9-IN-2

• Description :

  CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI (8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma (MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cdk9-in-2.html

• Purity :

  98.72

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  ClC1=CN=C(N[C@@H]2CC[C@@H](N)CC2)C=C1C3=NC(NCC4=CC(F)=CC=C4)=CC=C3

• Molecular Formula :

  C23H25ClFN5

• Molecular Weight :

  425.93

• References & Citations :

  [1]Michel Faure, et al. Pharmacodynamic markers associated with cyclin-dependent kinase inhibitors. From PCT Int. Appl. (2012), WO 2012131594A1

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK9

• CAS Number :

  [1263369-28-3]